0.8485
I Mab Adr stock is traded at $0.8485, with a volume of 106.23K.
It is up +2.18% in the last 24 hours and down -0.25% over the past month.
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
See More
Previous Close:
$0.8304
Open:
$0.8601
24h Volume:
106.23K
Relative Volume:
0.44
Market Cap:
$68.57M
Revenue:
$3.91M
Net Income/Loss:
$-206.53M
P/E Ratio:
-0.3418
EPS:
-2.4825
Net Cash Flow:
$-167.78M
1W Performance:
+0.85%
1M Performance:
-0.25%
6M Performance:
-36.20%
1Y Performance:
-52.86%
I Mab Adr Stock (IMAB) Company Profile
Compare IMAB with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
IMAB
I Mab Adr
|
0.8485 | 68.57M | 3.91M | -206.53M | -167.78M | -2.4825 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
492.42 | 124.91B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
587.85 | 60.05B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
594.65 | 35.88B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
241.97 | 29.83B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
249.13 | 24.58B | 3.81B | -644.79M | -669.77M | -6.24 |
I Mab Adr Stock (IMAB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-09-21 | Initiated | Siebert Williams Shank | Buy |
Jun-02-21 | Initiated | Daiwa Securities | Buy |
Mar-15-21 | Initiated | Needham | Buy |
Mar-03-21 | Reiterated | H.C. Wainwright | Buy |
Feb-25-21 | Initiated | Piper Sandler | Overweight |
Dec-07-20 | Initiated | H.C. Wainwright | Buy |
Jul-27-20 | Initiated | Cantor Fitzgerald | Overweight |
Feb-12-20 | Initiated | China Renaissance | Buy |
Feb-11-20 | Initiated | Jefferies | Buy |
View All
I Mab Adr Stock (IMAB) Latest News
After Plunging -20.33% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB) - Yahoo Finance
After Plunging -19.7% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB) - Yahoo Finance
I-Mab at Needham Conference: Strategic Transformation Unveiled - Investing.com
I-Mab at Needham Conference: Strategic Transformation Unveiled By Investing.com - Investing.com South Africa
I-Mab’s Transformative Year: Financial and Strategic Highlights - TipRanks
I-Mab stock price target lowered to $7 at H.C. Wainwright By Investing.com - Investing.com South Africa
I-Mab stock price target lowered to $7 at H.C. Wainwright - Investing.com India
I-Mab Reports Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire Inc.
I-Mab stock touches 52-week low at $0.72 amid market challenges - Investing.com
I-Mab faces Nasdaq delisting over bid price rule By Investing.com - Investing.com South Africa
I-Mab faces Nasdaq delisting over bid price rule - Investing.com
I-Mab advances gastric cancer treatment with swift trial enrollment - Investing.com
I-Mab stock touches 52-week low at $0.76 amid market challenges - Investing.com India
I-Mab ADR (IMAB) stock analysis: A simple moving average approach - US Post News
Use of failure mode and effect analysis to improve the monoclonal antibody drugs management process in pharmacy intravenous admixture services - Nature
I-Mab Chairman plans $2 million ADS purchase - Investing.com India
I-Mab’s Third Quarter Results: Progress in Cancer Immunotherapies - MSN
I-Mab names Sean Fu as new CEO - Investing.com India
Invitation: Vallourec Q3 2024 Results ReleaseConference Call on Friday, November 15, 2024 - The Manila Times
I-Mab ADR (NASDAQ: IMAB) Stock: Investors Need To Know This - Stocks Register
Would I Buy Spectral AI Inc (NASDAQ: MDAI) Stock At Any Time In The Future? - Stocks Register
If You Don’t Buy Hub Cyber Security Ltd (NASDAQ: HUBC) Now, You’ll Kick Yourself Later - Stocks Register
Itau Unibanco Holding S.A. ADR (NYSE: ITUB) Still Pointing Upwards - Stocks Register
Is Veritone Inc’s (NASDAQ:VERI) Stock On The Decline? - Stocks Register
Cisco Systems, Inc. (NASDAQ: CSCO): What’s Next After The Stock Plunge? - Stocks Register
Should This Give Tandem Diabetes Care Inc (NASDAQ: TNDM) Investors Sleepless Nights? - Stocks Register
Kinross Gold Corp. (NYSE: KGC) Investors Should Be Worried About This. - Stocks Register
Where Do Analysts See Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) Heading? - Stocks Register
Not A Good News For Keycorp (NYSE: KEY): The Stock Could Go Down -34.98 Percent More - Stocks Register
Analyst Forecast For Grab Holdings Limited (NASDAQ: GRAB) - Stocks Register
Asian Equities Traded in the US as American Depositary Receipts Advance in Thursday Trading - MSN
IMab (IMAB) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
Piper Sandler maintains Overweight rating on I-Mab stock on drug data - Investing.com
Piper Sandler cuts I-Mab stock target to $10, keeps overweight rating - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Minnelide combined with anti-ANGPTL3-FLD monoclonal antibody completely protects mice with adriamycin nephropathy by promoting autophagy and inhibiting apoptosis - Nature
I-Mab: Dropping Coverage - Morningstar
I-Mab Full-Year Update Uneventful; Potential Catalysts in H2 2023 - Morningstar
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022 - PR Newswire
Morningstar’s Best- and Worst-Performing Stocks: 2022 - Morningstar
Results for A amyloid PET SUVr and B Centiloid scale assessments from study 201 core - ResearchGate
The Cheapest Stock in the World - Morningstar.ca
10 of the Cheapest Stocks of 2022 - Morningstar
Why Are Some China Healthcare Stocks Up 50%? - HK.Morningstar.com
Fig. 3 A Scatchard analysis of 125 I-trastuzumab binding to human... - ResearchGate
Anti-ANGPTL3-FLD monoclonal antibody treatment ameliorates podocyte lesions through attenuating mitochondrial damage - Nature
The Best- and Worst-Performing Stocks: Q3 2022 - Morningstar
Fig. 2 Flowchart of Sicilian adverse drug reaction (ADR) report... - ResearchGate
Markets Brief: How High Can Mortgage Rates Go? - Morningstar
New 5-Star Stocks - Morningstar
HFCAA News: 128 Chinese Stocks the SEC Could Delist - InvestorPlace
I Mab Adr Stock (IMAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):